JP2022527482A5 - - Google Patents
Info
- Publication number
- JP2022527482A5 JP2022527482A5 JP2021557790A JP2021557790A JP2022527482A5 JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5 JP 2021557790 A JP2021557790 A JP 2021557790A JP 2021557790 A JP2021557790 A JP 2021557790A JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- erdafitinib
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025230741A JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166429.1 | 2019-03-29 | ||
| EP19166429 | 2019-03-29 | ||
| US201962833395P | 2019-04-12 | 2019-04-12 | |
| US62/833,395 | 2019-04-12 | ||
| PCT/EP2020/058814 WO2020201138A1 (en) | 2019-03-29 | 2020-03-27 | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Division JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527482A JP2022527482A (ja) | 2022-06-02 |
| JP2022527482A5 true JP2022527482A5 (enExample) | 2024-07-24 |
Family
ID=69954076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557790A Pending JP2022527482A (ja) | 2019-03-29 | 2020-03-27 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220175768A1 (enExample) |
| EP (2) | EP4548935A3 (enExample) |
| JP (2) | JP2022527482A (enExample) |
| KR (1) | KR20210143878A (enExample) |
| CN (1) | CN113645975A (enExample) |
| AU (1) | AU2020253054B2 (enExample) |
| BR (1) | BR112021019203A2 (enExample) |
| CA (1) | CA3130773A1 (enExample) |
| IL (1) | IL286727A (enExample) |
| JO (1) | JOP20210260A1 (enExample) |
| MA (1) | MA55486A (enExample) |
| MX (1) | MX2021011943A (enExample) |
| PH (1) | PH12021552352A1 (enExample) |
| SG (1) | SG11202109854RA (enExample) |
| WO (1) | WO2020201138A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4210702A1 (en) * | 2020-09-14 | 2023-07-19 | JANSSEN Pharmaceutica NV | Fgfr inhibitor combination therapies |
| CN117440800A (zh) * | 2021-06-07 | 2024-01-23 | R·P·舍勒科技有限责任公司 | 用于对水分敏感的药物组合物的保护性包衣 |
| IL312063A (en) | 2021-10-12 | 2024-06-01 | Taris Biomedical Llc | Ardafitinib formulations and systems for intravesical administration |
| KR20240145513A (ko) | 2022-02-18 | 2024-10-07 | 타리스 바이오메디컬 엘엘씨 | 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템 |
| CN116106240B (zh) * | 2022-12-26 | 2025-11-07 | 华中农业大学 | 一种尿液酪氨酸检测体系、检测方法及检测试剂盒 |
| KR20250143348A (ko) | 2023-02-13 | 2025-10-01 | 타리스 바이오메디컬 엘엘씨 | 방광암 치료에 사용하기 위한 방광내 투여용 에르다피티닙 |
| CN120731077A (zh) | 2023-02-17 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| KR102470456B1 (ko) | 2014-09-26 | 2022-11-23 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| TWI798199B (zh) * | 2017-02-06 | 2023-04-11 | 比利時商健生藥品公司 | 癌症治療 |
| HUE062453T2 (hu) * | 2017-02-06 | 2023-11-28 | Janssen Pharmaceutica Nv | Rákbetegség kezelése |
-
2020
- 2020-03-27 MA MA055486A patent/MA55486A/fr unknown
- 2020-03-27 EP EP24174999.3A patent/EP4548935A3/en active Pending
- 2020-03-27 JP JP2021557790A patent/JP2022527482A/ja active Pending
- 2020-03-27 KR KR1020217034729A patent/KR20210143878A/ko not_active Ceased
- 2020-03-27 BR BR112021019203A patent/BR112021019203A2/pt unknown
- 2020-03-27 CN CN202080026737.4A patent/CN113645975A/zh active Pending
- 2020-03-27 SG SG11202109854R patent/SG11202109854RA/en unknown
- 2020-03-27 US US17/598,985 patent/US20220175768A1/en active Pending
- 2020-03-27 PH PH1/2021/552352A patent/PH12021552352A1/en unknown
- 2020-03-27 AU AU2020253054A patent/AU2020253054B2/en active Active
- 2020-03-27 MX MX2021011943A patent/MX2021011943A/es unknown
- 2020-03-27 WO PCT/EP2020/058814 patent/WO2020201138A1/en not_active Ceased
- 2020-03-27 EP EP20713656.5A patent/EP3946340A1/en active Pending
- 2020-03-27 CA CA3130773A patent/CA3130773A1/en active Pending
-
2021
- 2021-09-23 JO JOP/2021/0260A patent/JOP20210260A1/ar unknown
- 2021-09-26 IL IL286727A patent/IL286727A/en unknown
-
2025
- 2025-12-04 JP JP2025230741A patent/JP2026048748A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527482A5 (enExample) | ||
| EP4337191B1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| CN109310754A (zh) | 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法 | |
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| Kanda et al. | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy | |
| Adhikaree et al. | Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy | |
| JP2025038167A (ja) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 | |
| Crown et al. | Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival | |
| JP2023513298A5 (enExample) | ||
| Alexandraki et al. | Medical therapy for craniopharyngiomas | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| Shihab et al. | Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study | |
| Fujimoto et al. | Successful treatment with ramucirumab plus erlotinib following osimertinib-induced interstitial lung disease | |
| Calvo et al. | Management of mTOR inhibitors oral mucositis: current state of knowledge | |
| US20220348662A1 (en) | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings | |
| Hashmi et al. | The effects of voriconazole on metabolism of all-trans retinoic acid in the treatment of acute promyelocytic leukemia: a case report | |
| JP2022527189A5 (enExample) | ||
| de Bono et al. | Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC) | |
| KR102895850B1 (ko) | Isa-2011b와 엘로티닙을 포함하는 암 예방 또는 치료를 위한 병용 투여용 약학적 조성물 | |
| Chiba et al. | Deterioration of glycemic control contributes to the prevalence of proteinuria among bevacizumab-treated cancer patients with type 2 diabetes mellitus | |
| CN117838700B (zh) | 一种治疗非小细胞肺癌的吉非替尼和土木香内脂组合物及制备包含其的药物的应用 | |
| Helwick | Emerging success with novel targeted therapies in endocrine-resistant metastatic breast cancer | |
| EP4452275B1 (en) | Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers |